A 2013 study on prostate cancer patients showed that the CCL5 serum levels were not different among patients groups: (i) negative prostate biopsy, (ii) initial diagnosis of prostate cancer, and (iii) taxane-resistant groups [186]. Here, CCL5 is linked to prostate carcinoma.